CervoMed (CRVO) EPS (Basic) (2010 - 2026)

CervoMed (CRVO) posted EPS (Basic) of -$0.88 for Q1 2026, up 2.02% sequentially from -$0.89 in Q4 2025, and down 42.92% YoY from -$1.54 in Q1 2025.

CervoMed (CRVO) EPS (Basic) (2010 - 2026) Analysis & Trends

CervoMed has reported EPS (Basic) for 17 years, with the latest figure at -$0.88 in Q1 2026.

Quarterly EPS (Basic) fell 42.92% year-over-year to -$0.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 (down 40.63% YoY) and the FY2025 annual result came in at -$2.98, down 32.44% from the prior year.
EPS (Basic) improved to -$0.88 in Q1 2026 per CRVO's latest filing, from -$0.89 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.35 in Q2 2024 and troughed at -$7.87 in Q4 2022.
A 5-year average of -$1.56 and a median of -$0.89 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2025: EPS (Basic) surged 87.49% in 2023, then slumped 112.64% in 2025.
Over 5 years, EPS (Basic) stood at -$7.87 in 2022, then soared by 87.49% to -$0.98 in 2023, then advanced by 7.99% to -$0.91 in 2024, then increased by 1.19% to -$0.89 in 2025, then gained by 2.02% to -$0.88 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.88, -$0.89, and -$0.83 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	CervoMed	26.12 Mn	26.12 Mn	-	-0.64

Download Data